Citadel Advisors’s Sight Sciences SGHT Stock Holding History

Citadel Advisors’s Portfolio SGHT Stock Details SGHT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,700	Closed	-$52.5K	–	13960
2025 Q2	$52.5K	Buy	+12,700	New	+$42.4K	﹤0.01%	11745
2025 Q1	–	Sell	-900	Closed	-$3.28K	–	15456
2024 Q4	$3.28K	Buy	900 +400	+80%	+$1.82K	﹤0.01%	14006
2024 Q3	$3.15K	Sell	500 -1,100	-69%	-$7.4K	﹤0.01%	13683
2024 Q2	$10.7K	Sell	1,600 -1,600	-50%	-$9.46K	﹤0.01%	13074
2024 Q1	$16.9K	Buy	+3,200	New	+$15K	﹤0.01%	13123
2023 Q2	–	Sell	-3,300	Closed	-$28.8K	–	15124
2023 Q1	$28.8K	Sell	3,300 -6,700	-67%	-$74.4K	﹤0.01%	12767
2022 Q4	$122K	Buy	+10,000	New	+$95.1K	﹤0.01%	10934

Other funds holding SGHT

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Americana Partners Houston, Texas $3.85B AUM 23.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BGI

B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Citadel Advisors's SGHT Position: Q1 2026 in Review

Citadel Advisors reduced its Sight Sciences (SGHT) stake by 8.5% in Q1 2026, selling an estimated $67.6K and leaving 135,303 shares worth $510K. The position accounts for ﹤0.01% of the portfolio, ranked #9255.

Citadel Advisors first reported a position in SGHT in Q3 2021 and has held it in 14 quarters since. The position peaked at $4.73M in Q4 2021. 114 funds tracked by Wall St. Rank hold SGHT as of Q1 2026.

Citadel Advisors held 135,303 shares of Sight Sciences worth $510K as of Q1 2026.
Citadel Advisors sold 12,535 Sight Sciences shares in Q1 2026, an estimated $67.6K.
Sight Sciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9255 holding.
Citadel Advisors first reported a position in Sight Sciences in Q3 2021 and has held it in 14 quarters since.
Citadel Advisors's Sight Sciences position peaked at $4.73M in Q4 2021.
114 funds tracked by Wall St. Rank held Sight Sciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.